Key terms
About BMEA
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BMEA news
Apr 04
2:48am ET
3 Best Stocks to Buy Now, 4/4/2024, According to Top Analysts
Apr 03
8:01am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Apr 02
7:30am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biomea Fusion (BMEA) and GoodRx Holdings (GDRX)
Apr 02
7:15am ET
Biomea Fusion (BMEA) Receives a Buy from Scotiabank
Apr 02
4:44am ET
Biomea Fusion downgraded to Neutral from Overweight at JPMorgan
Apr 02
3:50am ET
Analysts Offer Insights on Healthcare Companies: Humana (HUM), Baxter International (BAX) and Biomea Fusion (BMEA)
Apr 01
8:45pm ET
Promising Efficacy of Biomea Fusion’s BMF-219 in Type 1 Diabetes Treatment: A Positive Outlook on Early Clinical Data
Apr 01
12:05pm ET
Buy Rating Affirmed for Biomea Fusion on Promising BMF-219 Clinical Results and Strong Financial Position
Apr 01
9:08am ET
Biomea Fusion highlights initial data from type 1 patients dosed with BMF-219
Apr 01
9:04am ET
Biomea Fusion reports Q4 EPS (98c), consensus (85c)
Mar 22
1:20pm ET
Biomea Fusion options imply 6.2% move in share price post-earnings
Mar 22
7:20am ET
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Biomea Fusion (BMEA) and Soleno Therapeutics (SLNO)
Mar 19
8:45am ET
Largest borrow rate increases among liquid names
Mar 19
6:21am ET
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Intuitive Surgical (ISRG) and Sangamo Biosciences (SGMO)
Mar 19
3:52am ET
3 Best Stocks to Buy Now, 3/19/2024, According to Top Analysts
Mar 18
7:45am ET
Truist Financial Issues a Buy Rating on Biomea Fusion (BMEA)
Mar 15
1:19pm ET
Biomea Fusion options imply 9.9% move in share price post-earnings
Mar 11
2:19pm ET
Biomea Fusion options imply 6.6% move in share price post-earnings
Mar 07
7:41am ET
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR)
Mar 07
7:12am ET
Analysts Are Bullish on These Healthcare Stocks: RegenXBio (RGNX), Biomea Fusion (BMEA)
Mar 06
12:05pm ET
Buy Rating Affirmed for Biomea Fusion on Promising BMF-219 Clinical Trial Outcomes and Strong Safety Profile
Mar 06
5:19am ET
Biomea Fusion presents BMF-219 data from escalation phase of COVALENT-111 trial
Mar 05
7:15am ET
Scotiabank Keeps Their Buy Rating on Biomea Fusion (BMEA)
Mar 04
2:19pm ET
Biomea Fusion options imply 29.9% move in share price post-earnings
Feb 26
3:04pm ET
Biomea Fusion options imply 25.3% move in share price post-earnings
Feb 16
8:45am ET
Largest borrow rate increases among liquid names
Feb 07
8:45am ET
Largest borrow rate increases among liquid names
Feb 06
5:02pm ET
Dissecting My Biomea Fusion (NASDAQ:BMEA) Options Trade: Tips, Tricks, and Lessons Learned
Feb 06
7:47am ET
Biomea Fusion (BMEA) Receives a Buy from Oppenheimer
Feb 06
6:09am ET
Biomea Fusion initiated with a Buy at Truist
Jan 10
7:18am ET
Biomea Fusion (BMEA) Receives a Buy from Piper Sandler
No recent press releases are available for BMEA
BMEA Financials
Key terms
Ad Feedback
BMEA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BMEA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
